This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

GeneLink Reports 2009 Results Record Revenues Exceed $8.5M

ORLANDO, Fla., March 31 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK.OB, "the Company," or "GeneLink"), a leading consumer genomics biotech company, today reported financial results for the fiscal year ended December 31, 2009.

Financial Highlights:

  • Annual net sales increased by 34%,  $8,561,455 as compared to $6,377,433 in 2008;
  • 4 th Quarter net sales increased by 9.7%,  $2,341,736 as compared to $2,134,504 in the previous quarter;
  • 4 th Quarter net loss reduced by 29.6%, $552,093 as compared to $783,794 in the previous quarter.

Dr. Bernard Kasten, GeneLink's Executive Chairman stated, "2009 was an important year for GeneLink.  Buoyed by the desirability and superiority of our proprietary science and products, we took steps in the third quarter of 2009 to increase our profit margins."  Dr. Kasten added, "Even more importantly, in 2009 and early 2010 the Board of Directors of GeneLink implemented plans to expand the revenue base at GeneLink and hired Gary Beeman on February 17, 2010 as GeneLink's CEO to lead the effort.  Mr. Beeman has extensive experience growing pioneering technology companies, and has long been a supporter of GeneLink and GeneWize Life Sciences, Inc. ("GeneWize").   He has impressed the Board with his vision for the future of GeneLink."

Beeman added, "GeneLink has now proven the viability and market acceptance of genetically-guided wellness products.  We are steadily improving our financials and are now ready to take GeneLink to the next level of market penetration.  Our focus is to utilize the pioneering genetic research and capabilities at GeneLink to partner with an array of global private label customers and channel partners compatible with our current channel to market.  We believe that the healthcare industry now accepts that genetically-guided and customized wellness products are the future - and that GeneLink's 16 years of pioneering genetics research can help everyone participate in their own personalized health care.  As our products and science are able to benefit more and more health-conscious customers, the ultimate beneficiaries will be our shareholders."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
GNLK $0.00 0.00%
AAPL $124.24 0.70%
FB $83.01 0.11%
GOOG $555.17 -0.65%
TSLA $190.41 -2.00%


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs